The Supreme Court has rejected an effort to restrict how mifepristone, one of two drugs used in medication abortion, reaches patients across the country. The ruling preserves the ability of medical providers to mail the drug directly to women seeking to end pregnancies.
Mifepristone has been at the center of the abortion debate for years. The drug, approved by the FDA in 2000, works by blocking progesterone, a hormone necessary to sustain pregnancy. It is typically used alongside a second medication called misoprostol to complete a medication abortion.
The justices' decision protects a 2021 change by the Food and Drug Administration that eased restrictions on the drug's distribution. Under that change, mifepristone could be sent through the mail rather than requiring patients to pick it up in person at a clinic or doctor's office. This shift dramatically expanded access, particularly for women in rural areas or states with limited abortion services.
Lower courts had considered challenges to the FDA's relaxed rules, with some conservative groups arguing that easier access posed safety risks. The Supreme Court's refusal to intervene signals the justices will not use the judicial system to further restrict medication abortion availability.
The decision arrives as abortion access remains deeply fractured across the country. Since the Supreme Court eliminated the constitutional right to abortion in 2022, individual states have enacted sharply different rules. Some have banned abortion entirely, while others have protected or expanded access. Mail delivery of mifepristone has become a crucial workaround for women living in restrictive states.
Author James Rodriguez: "This ruling keeps a critical lifeline open for millions of American women, even as the political landscape around abortion continues to shift dramatically by state."
Comments